AbbVie (ABBV) Receivables - Net (2012 - 2026)
AbbVie (ABBV) reported Receivables - Net of $12.5 billion for Q1 2026, little changed year-over-year from $12.5 billion in Q1 2025, and down 0.87% quarter-over-quarter from $12.6 billion in Q4 2025.
AbbVie (ABBV) Receivables - Net (2012 - 2026) Analysis & Trends
AbbVie (ABBV) has 15 years of Receivables - Net data on file, last reported at $12.5 billion in Q1 2026.
- Receivables - Net for Q1 2026 came in at $12.5 billion, changed 0.02% year-over-year; the trailing twelve-month figure through Mar 2026 was $12.5 billion (changed 0.02% YoY), and the FY2025 annual result was $12.6 billion, up 15.29% from the prior year.
- Receivables - Net retreated to $12.5 billion in Q1 2026 per ABBV's latest filing, from $12.6 billion in the prior quarter.
- Over five years, Receivables - Net peaked at $12.8 billion in Q3 2025 and troughed at $10.7 billion in Q1 2022.
- A 5-year average of $11.7 billion and a median of $11.5 billion in 2023 frame the typical range for Receivables - Net.
- The sharpest annual moves came in 2022 and 2024: Receivables - Net increased 15.75% in 2022, then decreased 2.12% in 2024.
- A 5-year view of Receivables - Net shows it stood at $11.3 billion in 2022, then fell by 0.88% to $11.2 billion in 2023, then slipped by 2.12% to $10.9 billion in 2024, then climbed by 15.29% to $12.6 billion in 2025, then decreased by 0.87% to $12.5 billion in 2026.
- Business Quant data shows ABBV's Receivables - Net at $12.5 billion in Q1 2026, $12.6 billion in Q4 2025, and $12.8 billion in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Gsk | 93,699,046.73 Bn | 93,699,041.77 Bn | 7.76 Bn |
| 2 | Eli Lilly | 1,012.06 Bn | 1,006.77 Bn | 16.22 Bn |
| 3 | Johnson & Johnson | 560.67 Bn | 538.62 Bn | 15.96 Bn |
| 4 | AbbVie | 402.20 Bn | 392.85 Bn | 10.78 Bn |
| 5 | Merck | 298.59 Bn | 292.94 Bn | 12.09 Bn |
| 6 | Amgen | 188.77 Bn | 176.74 Bn | 5.87 Bn |
| 7 | Gilead Sciences | 160.22 Bn | 152.49 Bn | 5.52 Bn |
| 8 | Pfizer | 148.19 Bn | 135.42 Bn | -1.21 Bn |
| 9 | Bristol Myers Squibb | 116.72 Bn | 106.26 Bn | 8.07 Bn |
| 10 | Novartis Ag | 109.78 Bn | 109.09 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 12.48 Bn |
| Mar 31, 2026 | 12.48 Bn |
| Dec 31, 2025 | 12.59 Bn |
| Dec 31, 2025 | 12.59 Bn |
| Sep 30, 2025 | 12.77 Bn |
| Sep 30, 2025 | 12.77 Bn |
| Jun 30, 2025 | 12.64 Bn |
| Jun 30, 2025 | 12.64 Bn |
| Mar 31, 2025 | 12.48 Bn |
| Mar 31, 2025 | 12.48 Bn |
| Dec 31, 2024 | 10.92 Bn |
| Dec 31, 2024 | 10.92 Bn |
| Sep 30, 2024 | 11.47 Bn |
| Sep 30, 2024 | 11.47 Bn |
| Jun 30, 2024 | 11.72 Bn |
| Jun 30, 2024 | 11.72 Bn |
| Mar 31, 2024 | 11.95 Bn |
| Mar 31, 2024 | 11.95 Bn |
| Dec 31, 2023 | 11.16 Bn |
| Dec 31, 2023 | 11.16 Bn |